INTRODUCTION
The site of synthesis of antihemophilic factor (AHF, Factor VIII)> is not known. Previous studies have suggested the possibility that organs such as liver (1) (2) (3) , spleen (1, 2. 4, 5) . or kidney (6) and cells such as reticuloendothelial cells (7) or l!ymnphocytes (8) might be sites of production; however, the evidence for these claims is indirect and is subject to sev-eral interpretations.
Received for publication 6 April 1973 and in revised form 10 July 1973. 'Abbreviations Used in this paper: AHF, antihemophilic factor (Factor VIII); FCS, fetal calf serum; PBS, phosphate-buffered saline; TC 199, 'Medium 199. Recent imni111un1oflUorescence studies performed on a variety of human tissue sections, using a monospecitic rabbit antihluman AHF, have demonstrated that endothelial cells contain AHF antigen (9) (10) (11) . The development in our laboratory of methods for culturing and identifying human endothelial cells (12, 13) has made it lossible to examine the role of the endothelial cell in AHF synthesis.
Our results show that AHF antigen, as identified by a radioimmunoassay, is found in cultured endothelial cells and in the culture medium obtained from these cells. Radioactive amino acids were incorporated into the AHF antigen present in the culture medium indicating that endothelial cells synthesize and release a protein (or proteins) that shares antigens present on normal human AHE.
METHODS
Cell culture techniqutcs and cdlture media. Human endothelial cells and blood vessel medial smooth muscle cells both derived from umbilical cord veins, and fibroblasts derived from adult human abdominal skin were cultured using methods and materials described in the accompanying paper (13) . Endothelial cells were cultured in Medium 199 (TC 199) Imnunofluorescencc stndies. Specimens of umbilical cord and monolayers of cultured endothelial cells that had been cultured from 3 days to 4 wvk were prepared by the methods described in the preceding paper (13) . Monospecific rabbit antihuman AHF was prepared as previously described (14) . Fluorescein-conjugated goat antirabbit globulin (Hvland Div., Travenol Laboratories, Costa Mesa, Calif.) was use l to localize the bound rabbit anti-AHF. Before treatment with antisera, sections were immersed for 10 min in phosphate-buffered saline ([PBS] 0.145 M NaCl, 0.01 NM phosphate, pH 7.0). Excess buffered saline was removed from the slide, and a drop of a 1: 16 dilution of either rabbit
The Journal of Clinical Investigation Volume 52 November 1973 *2757-2764 anti-AHF serum or normal rabbit serum sufficient to cover the section of tissue was added. The slide was incubated for 30 min at room temperature, and the sections were washed for 1 h at room temperature with one change of buffered saline. The staining and washing procedure was then repeated using a 1: 16 dilution of the fluorescein-conjugated goat antirabbit globulin. The washed sections were covered with one drop of 10% glycerol-90% buffered saline and a cover slip and examined in a Leitz Ortholux photomicroscope (E. Leitz, Inc., Rockleigh, N. J.) using a HBO 200 W mercury vapor lamp, a UG 1 (2 mm) exciter filter, and a Leitz UV absorbing barrier filter (15) . Photographs were taken using Tri-X Pan film (Eastman Kodak Co., Rochester, N. Y.).
Radioimmnnoassay of AHF antigen. Radioimmunoassay of AHF antigen was performed using purified 125I-labeled rabbit anti-AHF. The preparation and characterization of the antiserum and the details of the assay have been published (14) . The assay sensitivity is such that AHF concentrations as low as 0.2% of those in normal human plasma can be detected. For this assay, 1 AHF antigen unit is defined as that amount of antibody-binding material present in 1 ml of a pooled normal human plasma standard, the preparation of which has been described (14) . AHF antigen determinations were carried out using undiluted samples of media stored at -70'C before assay. Rabbit anti-AHF has been shown by others to have little reactivity against bovine AHF (16, 17) , and there was no detectable AHF antigen in the preculture medium that contained 20% FCS (Table I) End-group analysis of ['4C] leucine containing material from cultured endothelial cells. For end-group analysis, previously outlined procedures were followed (20, 21) . Endothelial cells were cultured with 0.5 /hCi/ml of ['4C]-leucine, sp act-304 mCi/mmol, (New England Nuclear) for 24 h. The culture medium was removed and brought to 100% saturation by the addition of solid ammonium sulfate.
The mixture was incubated 1 h at 20'C and centrifuged at 40,000 g for 15 min, and the precipitate was dissolved in PBS. The residual cell monolayer was detached from the Petri dish by incubation with cord buffer containing 0.01% EDTA and 0.1% collagenase for 15 min at 370C. The cells were washed into cord buffer containing 0.2% collagenase and 0.001 M CaCl2 and were then incubated for 15 min at 37°C. The cells were washed once in 0.2% EDTA-diluent buffer, resuspended in 3 ml of this solution, frozen and thawed three times, and centrifuged at 40,000 g for 15 min. The cell supernate was removed, and the cell pellet was resuspended in 3 ml PBS. The three samples (the protein fraction from the postculture medium and the cell-derived soluble and particulate pellet fractions) were exhaustively dialyzed against 0.05 M NH4HCO3 (pH 7.9). 3-ml samples of all three fractions were shaken at 220C for 2 h with 2 ml of a 5% solution of dinitrofluorobenzene in ethanol. The samples were acidified (pH < 2) with 0.05 ml 12 N HC1, and the unreacted reagent was extracted with ether. The protein in the aqueous phase was precipitated with TCA, washed with ethanol-ether (1: 3, vol/vol), washed with ether, and dried under nitrogen. The protein was completely hydrolyzed in 6 N HCI for 22 h at 1100C in sealed tubes.
In order to extract any dinitrophenyl-leuicine, the hydrolysate was shaken three times with 2 ml of ether. After evaporation, both the ether extract and the remaining aqueous material were counted in the liquid scintillation spectrometer. Complete recovery of the radioactivity in the samples was obtained.
Iiicorporation , and centrifuged at 12,000 g for 20 min. The precipitate was washed three times with 50% saturated ammonium sulfate and then dissolved in PBS at 1/10th the original sample volume. 3 ml of this concentrated material was chromatographed on a 1.6 X 60 cm column of Sepharose 6B using barbital-buffered saline (14) . The AHF antigen-rich void volume fractions were pooled and concentrated to 2 ml by precipitation with 50% saturated ammonium sulfate before dialysis against barbital-buffered saline (14) .
Immunoprecipitate determinations were carried out using a globulin fraction prepared from the monospecific rabbit anti-AHF by precipitation of serum proteins with 50%o saturated ammonium sulfate. Control studies were carried out using the same concentration of globulin (0.13-1.25 mg/ml) prepared in the same way from normal rabbit serum or from rabbit serum obtained from an animal that had been immunized with sulfanilic acid coupled to bovine serum albumin. 11 ml of unlabeled rabbit anti-AHF globulin (or control globulin) was added to 0.2 ml of the concentrated, labeled culture medium proteins, and the mixture was incubated at 370C for l h and at 4°C overnight.
nil of undiluted goat antirabbit gamma globulin (Hyland Div., Travenol Laboratcries) was then added, and the tubes were again incubated at 37°C for 1 h and at 4°C overnight. It has been shown previously that certain cells including thyroid (25) , liver (26) , and bacterial cells (27) (Table V) . t High molecular weight proteins from each culture medium were incubated with either monospecific rabbit anti-AHF globulin or normal rabbit globulin, both at 0.63 mg/ml. Goat antirabbit globulin was subsequently added, and the radioactivity of the immune precipitates was determined.
Values expressed are in counts per minute per milliliter of high molecular weight fractions.
However, the endothelial cells did release AHF antigen in an amount similar to that found when endothelial cells were cultured for 72 h in TC 199 containing 20% regular FCS (Table I) . AHF procoagulant activity and AHF antigen were both absent in preculture media.
To determine if newly synthesized AHF was inactivated in the culture system, culture medium containing exogenous AHF (0.7 U/ml) was either incubated alone or with endothelial cells and then assayed for AHF procoagulant activity. After 72 h of incubation, AHF pro- coagulant activity was present in the media at levels consistent with the amounts of exogenous AHF added (Table V). These experiments were repeated using exogenous AHF at concentrations that more closely approximated the AHF antigen concentration of postculture media (0.07 U/ml) (Table I) . Again, AHF procoagulant activity was not inactivated during the period of incubation (Table V) . In a separate set of similar experiments (not shown) it was demonstrated that AHF antigen levels remained constant during the incubation period. Thus neither AHF antigen nor the AHF procoagulant activity were significantly degraded during the 72 h incubation period.
To determine whether trace amounts of thrombin could activate the AHF antigen in the postculture medium as has been described for AHF (24, 28) , experiments were performed in which the postculture medium was incubated with varying thrombin concentrations (0.2-0.035 U/ml). No procoagulant activity was generated from the AHF antigen present in the postculture medium.
DISCUSSION
The studies reported here demonstrate synthesis and release of macromolecular AHF antigen by cultured human endothelial cells. These observations are compatible with the recent demonstration of AHF antigen in endothelial cells throughout the body (9) (10) (11) . Control immunofluorescence and radioimmunoassay studies have established that cultured fibroblasts and smooth muscle cells do not have this capacity.
It is recognized that the validity of the radioimmunoassay and immunofluorescence studies is dependent upon the specificity of the rabbit anti-AHF. Four kinds of evidence indicate that this antibody reacts with the same molecule in human plasma as that which is responsible for AHF procoagulant activity. The most direct is the demonstration that the absorbed antiserum, which inactivates AHF procoagulant activity, forms a single line in immunodiffusion studies with AHF-rich concentrates of normal human plasma (16 (b) The immaturity of the fetal endothelial cells and/ or the artificial conditions of the culture might affect AHF antigen synthesis in a way that would prevent the development of AHF procoagulant activity. Full-term newborns have normal levels of plasma AHF procoagulant activity even though AHF does not cross the placenta (33, 34) . It can be assumed, therefore, that the full-term fetus can synthesize functional AHF. However, it is possible that endothelial cells in various anatomic regions are functionally heterogeneous. In addition, it is possible that the culture conditions limited AHF procoagulant synthesis. The refutation of these possibilities would require studies in which the endothelial cells were derived from adult arteries or veins as well as studies in which a variety of different culture media were utilized. These have yet to be carried out.
(c) Endothelial cells may synthesize an inactive "precursor" molecule. If (38) . Nonfunctional high molecular weight material-greater than 2,000,000 daltons-is detected by AHF radioimmunoassay when AHF is dissociated by these conditions during agarose gel chromatography or sucrose density ultracentrifugation. In contrast, AHF procoagulant activity is limited to low molecular weight proteins-approximately 150,000 daltons-that cannot be detected by radioimmunoassay or electroimmunoassay (38) . Human and rabbit antibodies inactivate the AHF procoagulant activity of the low molecular weight subunits, however, and are neutralized by the antigenic de- terminants present on the nonfunctional high molecular weight subunits (38) . The 
